Raza A - Search Results

1

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR. Ebert BL, et al. Among authors: raza a. Nature. 2008 Jan 17;451(7176):335-9. doi: 10.1038/nature06494. Nature. 2008. PMID: 18202658 Free PMC article.

2

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A. Ebert BL, et al. Among authors: raza a. PLoS Med. 2008 Feb;5(2):e35. doi: 10.1371/journal.pmed.0050035. PLoS Med. 2008. PMID: 18271621 Free PMC article.

3

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Kumar MS, et al. Among authors: raza a. Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26. Blood. 2011. PMID: 21873545 Free PMC article.

4

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Raza A, Galili N. Raza A, et al. Nat Rev Cancer. 2012 Dec;12(12):849-59. doi: 10.1038/nrc3321. Nat Rev Cancer. 2012. PMID: 23175121 Review.

5

Lenalidomide for myelodysplastic syndromes: finally, hope not hype.

Raza A, Galili N. Raza A, et al. Nat Clin Pract Oncol. 2005 Aug;2(8):390-1. doi: 10.1038/ncponc0244. Nat Clin Pract Oncol. 2005. PMID: 16130932 No abstract available.

6

Immunomodulatory drugs in myelodysplastic syndromes.

Galili N, Raza A. Galili N, et al. Among authors: raza a. Expert Opin Investig Drugs. 2006 Jul;15(7):805-13. doi: 10.1517/13543784.15.7.805. Expert Opin Investig Drugs. 2006. PMID: 16787143 Review.

7

Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Galili N, Cerny J, Raza A. Galili N, et al. Among authors: raza a. Curr Treat Options Oncol. 2007 Apr;8(2):117-28. doi: 10.1007/s11864-007-0017-1. Curr Treat Options Oncol. 2007. PMID: 17634837 Review.

8

Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.

Galili N, Raza A. Galili N, et al. Among authors: raza a. Best Pract Res Clin Haematol. 2009 Jun;22(2):223-37. doi: 10.1016/j.beha.2009.04.006. Best Pract Res Clin Haematol. 2009. PMID: 19698930

9

Clinical effect of point mutations in myelodysplastic syndromes.

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Bejar R, et al. Among authors: raza a. N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343. N Engl J Med. 2011. PMID: 21714648 Free PMC article.

10

The biology and treatment of myelodysplastic syndromes.

Raza A, Galili N. Raza A, et al. Rinsho Ketsueki. 2013 Oct;54(10):1730-6. Rinsho Ketsueki. 2013. PMID: 24064823 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,678 results

Search Page